A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus
Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in
Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small
Lymphocytic Lymphoma

An open-label, multi-center, first in human phase I global dose escalation and expansion study of INR731 single agent or in combination with ARPI in patients with metastatic prostate cancer

 Achieving viral CLEARance in immunocompromised long-term shedders of SARS-CoV 2 - an open-label randomized trial“ (Prüfplan-Code: CLEAR)

Langzeitnachbeobachtung von Patienten mit CLL, B-PLL, T-PLL, SLL, T/NK-LGL, HCL und Richter Transformation

EINE PROSPEKTIVE, OFFENE, MULTIZENTRISCHE, RANDOMISIERTE PHASE-3-STUDIE MIT ACALABRUTINIB, OBINUTUZUMAB UND VENETOCLAX (GAVE) IM VERGLEICH ZU OBINUTUZUMAB UND VENETOCLAX (GVE) BEI ZUVOR UNBEHANDELTEN PATIENTEN MIT HOCHRISIKO (17P-DELETION, TP53-MUTATION ODER KOMPLEXEM KARYOTYP) CHRONISCHER LYMPHATISCHER LEUKÄMIE (CLL): CLL-16 STUDIE DER DCLLSG

A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes

A prospective observational trial to assess treatment sequences and factors that impact
overall survival in patients with chronic lymphocytic leukaemia (CLL) treated within first-line
studies of the GCLLSG

Beobachtungsstudie zum Verlauf der CML unter den neuen Erstlinientherapien

Ivosidenib in combination with Azacitidine as first-line treatment for adult patients with newly diagnosed AML with an IDH1 R132 mutation who are not eligible to receive standard induction chemotherapy: A prospective, longitudinal, multicenter, observational study in Germany.